Last Updated : August 15, 2019
Details
Generic Name:
tezacaftor/ivacaftor
Project Status:
Not filed
Therapeutic Area:
Cystic fibrosis, F508del mutation(s)
Manufacturer:
Vertex Pharmaceuticals Canada Inc.
Brand Name:
Symdeko
Project Line:
Reimbursement Review
Project Number:
NS0008-000
Submission Type:
Non Submission
Fee Schedule:
N/A
Indications:
Cystic fibrosis, F508del mutation(s)
Recommendation Type:
Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.
Last Updated : August 15, 2019